The Clearity Foundation was launched in 2008 to help ovarian cancer patients and their physicians make better-informed treatment decisions based on the molecular profile of the tumor (the “tumor blueprint”). Our goal is to help women with recurrent ovarian cancer live longer, healthier lives by enabling a more individualized approach to therapy selection.
A tumor blueprint provides information about tumor characteristics at the molecular level. This genomic analysis can help prioritize drugs that are more likely to be effective for an individual patient.
Since inception, Clearity has helped to empower hundreds of women with information to individualize treatment based on their unique tumor blueprints.